Vildagliptin 50mg + Metformin 500mg
TinMet brings together two renowned antidiabetic agents: Vildagliptin and Metformin. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormones’ effects, leading to improved insulin release and reduced glucagon secretion. Metformin, on the other hand, primarily targets insulin resistance and hepatic glucose production. The symbiotic effect of these two agents results in a medication that addresses multiple facets of type 2 diabetes.
The introduction of TinMet brings several notable benefits to the table:
Enhanced Efficacy: TinMet’s formulation offers enhanced potency, requiring lower doses to achieve the desired therapeutic effect.
Extended Duration: TinMet’s sustained action ensures a prolonged impact on blood sugar regulation, leading to fewer dosing frequencies.
Improved Tolerability: The innovative composition of TinMet minimizes potential side effects, enhancing patient adherence to treatment plans.
Personalized Approach: TinMet allows for tailored treatment strategies, catering to individual patient needs and response.